Matrix Laboratories Limited announced that it has been selected by the Clinton HIV/AIDS Initiative (CHAI) under its UNITAID-funded projects as the primary supplier of five antiretroviral (ARVs) drugs used in the secondline HIV/AIDS treatment regiments.
It also has been selcted as the primary supplier of seven ARVs used for peadiatric treatment.
Matrix chairman Robert J Coury said that Mylan and Matrix were committed to increasing access for patients in developing countries through its innovations and expertise.
According to the UNAIDS, an estimated 33 million people in the world are infected with HIV and more than 90 per cent of these patients in developing worlk and less than 4 million patients receive treatment.
He said that 30 per cent of the patients in developing countries depend on Matrix ARV products, according to a release.
Matrix's second-line products selected for the 2009 UNITAID-CHAI projects include heat-stable Lopinavir/Ritonarvir, the release added.